

Remarks


The foregoing amendments to the specification are to insert the priority application information, for which this application claims benefit. The Abstract has been added as a separate sheet, and should be inserted following the claims in the specification.

The amendments to the claims re-define the scope of the invention. No new matter has been added.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(609) 627-8508



Joseph T. Majka
Attorney for Applicants
Reg. No. 30,570

Date: April 28, 2006